Severe and moderate haemophilia A and B in US females
- PMID: 24533955
- DOI: 10.1111/hae.12364
Severe and moderate haemophilia A and B in US females
Abstract
Haemophilia A and B are rare X-lined hemorrhagic disorders that typically affect men. Women are usually asymptomatic carriers, but may be symptomatic and, rarely, also express severe (factor VIII (FVIII) or factor IX (FIX) <0.01 U mL(-1)) or moderately severe (FVIII/FIX 0.01-0.05 U mL(-1)) phenotypes. However, data on clinical manifestations, genotype and the psychosocial ramifications of illness in severely affected females remain anecdotal. A national multi-centre retrospective study was conducted to collect a comprehensive data set on affected US girls and women, and to compare clinical observations to previously published information on haemophilic males of comparable severity and mildly affected haemophilic females. Twenty-two severe/moderate haemophilia A/B subjects were characterized with respect to clinical manifestations and disease complications; genetic determinants of phenotypic severity; and health-related quality of life (HR-QoL). Clinical data were compared as previously indicated. Female patients were older than male patients at diagnosis, but similarly experienced joint haemorrhage, disease- and treatment-related complications and access to treatment. Gynaecological and obstetrical bleeding was unexpectedly infrequent. F8 or F9 mutations, accompanied by extremely skewed X-chromosome inactivation pattern (XIP), were primary determinants of severity. HR-QoL was diminished by arthropathy and viral infection. Using systematic case verification of participants in a national surveillance registry, this study elucidated the genetics, clinical phenotype and quality of life issues in female patients with severe/moderate haemophilia. An ongoing international case-controlled study will further evaluate these observations. Novel mechanistic questions are raised about the relationship between XIP and both age and tissue-specific FVIII and FIX expression.
Keywords: females; genotype; haemophilia A; haemophilia B; moderate haemophilia; severe haemophilia.
© 2014 John Wiley & Sons Ltd.
Similar articles
-
Similar bleeding phenotype in young children with haemophilia A or B: a cohort study.Haemophilia. 2014 Nov;20(6):747-55. doi: 10.1111/hae.12470. Epub 2014 Jun 3. Haemophilia. 2014. PMID: 24893572
-
Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.Thromb Haemost. 2000 Mar;83(3):433-7. Thromb Haemost. 2000. PMID: 10744150
-
[Haemophilia].Ned Tijdschr Geneeskd. 2014;158:A7357. Ned Tijdschr Geneeskd. 2014. PMID: 25351381 Review. Dutch.
-
X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.Eur J Hum Genet. 2021 Feb;29(2):241-249. doi: 10.1038/s41431-020-00742-4. Epub 2020 Oct 20. Eur J Hum Genet. 2021. PMID: 33082527 Free PMC article.
-
Renal diseases in haemophilic patients: pathogenesis and clinical management.Eur J Haematol. 2013 Oct;91(4):287-94. doi: 10.1111/ejh.12134. Epub 2013 Jun 28. Eur J Haematol. 2013. PMID: 23651176 Review.
Cited by
-
Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.Res Pract Thromb Haemost. 2023 Oct 21;7(8):102239. doi: 10.1016/j.rpth.2023.102239. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193069 Free PMC article.
-
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.Blood. 2024 Apr 4;143(14):1355-1364. doi: 10.1182/blood.2023021832. Blood. 2024. PMID: 38127586 Free PMC article. Clinical Trial.
-
Skewed X-inactivation is associated with retinal dystrophy in female carriers of RPGR mutations.Life Sci Alliance. 2023 Aug 4;6(10):e202201814. doi: 10.26508/lsa.202201814. Print 2023 Oct. Life Sci Alliance. 2023. PMID: 37541846 Free PMC article.
-
Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions.Int J Mol Sci. 2023 Jul 24;24(14):11846. doi: 10.3390/ijms241411846. Int J Mol Sci. 2023. PMID: 37511607 Free PMC article. Review.
-
Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.J Manag Care Spec Pharm. 2023 Jun;29(6):626-634. doi: 10.18553/jmcp.2023.29.6.626. J Manag Care Spec Pharm. 2023. PMID: 37276033 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous

